What is tesamorelin?
Tesamorelin is a synthetic analog of growth hormone-releasing hormone (GHRH) — your hypothalamus's natural signal to the pituitary to release GH. Unlike most peptides in this space, tesamorelin has FDA approval: it's marketed as Egrifta SV, indicated specifically for excess visceral fat in adults with HIV-associated lipodystrophy. That approval is built on multiple Phase III randomized controlled trials — the strongest evidence base of any GHRH peptide available.
What makes tesamorelin particularly relevant right now is its specificity for visceral fat. While GLP-1 agonists like semaglutide and GLP-3 compounds like retatrutide produce total body weight loss with visceral fat reduction as a downstream effect, tesamorelin targets visceral fat directly through a different mechanism — GH-driven lipolysis in visceral adipose tissue. This specificity makes it especially interesting for users at healthy body weight but carrying disproportionate visceral fat, and for users transitioning from GLP-1 class protocols who want targeted visceral fat maintenance.
Phase III trials in HIV-associated lipodystrophy showed average visceral fat reductions of 15–20% measured by CT imaging — objective measurement, not self-report. More recently, a 2022 NEJM Evidence RCT showed significantly reduced liver fat in people with NAFLD at risk for NASH — the same population that retatrutide's MASLD data speaks to, via a different mechanism.
For biohackers, the key considerations: tesamorelin has the strongest clinical evidence base in the GHRH peptide class. The trade-off is daily injection and the need for medical oversight for on-label use. Off-label use via compounding is widespread, with the same sourcing quality concerns that apply to all research-grade peptides.
How it works
GHRH Receptor Activation
Tesamorelin binds to GHRH receptors on anterior pituitary somatotroph cells, activating adenylyl cyclase → cAMP → PKA signaling. This triggers pulsatile GH secretion. The trans-3-hexenoic acid modification on tesamorelin's N-terminus protects it from DPP-4 degradation — the same enzyme that rapidly clears native GHRH — extending active half-life to 26–38 minutes vs. under 5 minutes for unmodified GHRH.
GH-Driven Visceral Lipolysis
GH activates hormone-sensitive lipase (HSL) in visceral adipose tissue, driving hydrolysis of stored triglycerides. Visceral adipose tissue is particularly GH-responsive compared to subcutaneous fat — which explains the specificity of tesamorelin's effect. This is direct lipolysis, not secondary to caloric restriction or appetite suppression. CT imaging in Phase III trials confirmed selective visceral fat reduction with minimal subcutaneous fat change.
IGF-1 and Metabolic Improvements
GH elevation stimulates hepatic IGF-1 production, contributing to improved lipid profiles (reduced triglycerides, increased HDL), improved insulin sensitivity, and the liver-fat reduction seen in NAFLD trials. IGF-1 also supports lean mass preservation — an important consideration in protocols focused on visceral fat without overall weight loss. Like ipamorelin and CJC-1295 (no-DAC), tesamorelin produces pulsatile GH release, preserving receptor sensitivity and natural negative feedback loops.
What the research shows
Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in HIV-infected patients with excess abdominal fat — pooled Phase 3 analysis
Falutz J et al.
Pooled analysis of two multicenter, double-blind, placebo-controlled Phase 3 trials in HIV patients with excess abdominal fat. Tesamorelin cut visceral adipose tissue ~15% versus placebo at 26 weeks (sustained to ~17.5% at 52 weeks on continued treatment), with triglyceride improvements. The efficacy/safety foundation for FDA approval.
View on PubMed →Effects of tesamorelin in HIV-infected patients with abdominal fat accumulation — a randomized placebo-controlled trial with a safety extension
Falutz J et al.
The second pivotal Phase 3 tesamorelin trial, with a 52-week safety extension. Visceral fat fell 10.9% vs. 0.6% on placebo at 6 months and ~18% by 12 months in those who kept taking it — but the reduction reversed quickly when patients switched to placebo. Establishes the durability pattern: the fat-reducing effect requires continued use.
View on PubMed →Effects of tesamorelin on non-alcoholic fatty liver disease in HIV — a randomised, double-blind, multicentre trial
Stanley TL et al.
RCT in people with HIV and NAFLD. Tesamorelin reduced hepatic fat fraction ~37% (−4.1% absolute vs. placebo, p=0.018), and 35% of the tesamorelin group dropped below 5% liver fat versus 4% on placebo. Key human evidence for the NAFLD/NASH liver-fat indication.
View on PubMed →Metabolic effects of a growth hormone-releasing factor in patients with HIV
Falutz J et al.
The pivotal NEJM randomized trial: 412 HIV patients with abdominal fat accumulation. Tesamorelin reduced visceral adipose tissue 15.2% versus a 5.0% increase on placebo at 26 weeks (CT-measured primary endpoint), with improved triglycerides and IGF-1. A cornerstone of the tesamorelin (EGRIFTA) approval package.
View on PubMed →What the community reports
Tesamorelin has a smaller but highly engaged user community compared to BPC-157 or CJC-1295 — primarily because its FDA approval means some users access it through legitimate medical channels (off-label prescriptions), bringing a different level of protocol rigor than typical research-chem communities. The reports are consistent and well-calibrated.
GLP-1 TO GLP-3 CONTEXT
Users transitioning from semaglutide or tirzepatide protocols often consider tesamorelin for targeted visceral fat maintenance. For users who want to push further — including the triple-receptor mechanism that directly drives hepatic lipolysis — see retatrutide (GLP-3).
Biology is individual. Visceral fat is influenced by cortisol, sleep, diet quality, and training — tesamorelin amplifies the results of a metabolically healthy lifestyle. Users who track consistently find it most effective alongside caloric discipline and resistance training.
Common misconceptions
"Tesamorelin will help me lose overall weight."
Tesamorelin specifically reduces visceral fat via GH-driven lipolysis in visceral adipose tissue. It produces modest or no subcutaneous fat loss and no significant appetite suppression. If your goal is overall weight loss, GLP-1 class compounds are more appropriate. Tesamorelin excels at visceral fat specifically.
"Because it's FDA-approved, it's available anywhere."
Egrifta SV is FDA-approved for HIV-associated lipodystrophy specifically. Off-label prescriptions for other indications require a physician willing to prescribe off-label. Compounded tesamorelin from research vendors has no FDA quality oversight and variable purity.
"Tesamorelin and CJC-1295 do the same thing."
Both are GHRH analogs that stimulate pituitary GH release. The differences: tesamorelin has FDA-approved formulation with clinical-grade manufacturing and Phase III RCT evidence for specific visceral fat efficacy. CJC-1295 has longer half-life options (DAC form) and more community experience. For visceral fat specifically, tesamorelin's clinical evidence is stronger.
"Results will appear in 2–4 weeks."
Phase III trials measured significant visceral fat reduction at 26 weeks, with continued improvement at 52 weeks. Community reports suggest noticeable waist circumference changes around weeks 8–12. Monthly progress tracking is more appropriate than weekly.
"Stopping tesamorelin maintains the results."
Discontinuation studies show partial reversal of visceral fat reduction after stopping — the fat comes back over months. This is consistent with how GH-driven lipolysis works; it's an active ongoing process, not a one-time change. Long-term use or cycling strategies are part of protocol design.
Open PepperLedger to track your visceral fat protocol →
Free to join. No credit card. Ask the Researcher how tesamorelin fits your current stack.
Free to join · No credit card · 23-day Pro trial included
Registered trials and extra catalog links. These are not Study cards — a registry page is not proof of efficacy.
- ClinicalTrials.gov · completed · NCT00608023Tesamorelin in HIV-associated lipodystrophy (EGRIFTA program)
- ClinicalTrials.gov · recruiting · NCT03150511Tesamorelin for functional recovery after peripheral nerve injury